Amylyx Pharmaceuticals, Inc.
AMLX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001658551
In the last 90 days, Amylyx Pharmaceuticals, Inc. insiders filed 0 open-market purchases and 9 sales; 206 institutions reported holding it in 13F filings for Q2 2026, worth $2.07B in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 12, 2026
- $3.84B
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $11.0M in total
- 9
- 13F holdersQ2 2026, +37 vs. previous quarter
- 206
- 13F valueReported value at the end of Q2 2026
- $2.07B
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- $0
- −100.0% year over year
- Net income, FY2025
- -$144.7M
- No comparable prior period
- Free cash flow, FY2025
- -$123.5M
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 12.8M
- Shares sold short
- Change
- −426.1K
- −3.2% vs. previous
- Days to cover
- 10.47
- At average daily volume
Superinvestors holding AMLX, Q2 2026
Go to the superinvestors tabNo superinvestor reported holding AMLX at the end of Q2 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Amylyx Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Nov 12, 2026 (view filing)4:00 PM ET | Nov 9-10 | 3 days | Frates James MChief Financial Officer | SSale | −40.0K | $30.19 | −$1.21M | −14.6%233.6K after | 4 lots10b5-1 |
| Nov 12, 2026 (view filing)4:00 PM ET | Nov 9 | 3 days | Klee Justin B.Co-Chief Executive Officer | SSale | −100.0K | $29.84 | −$2.98M | −2.8%3.51M after | 2 lots10b5-1 |
| Nov 12, 2026 (view filing)4:00 PM ET | Nov 9 | 3 days | Cohen Joshua BCo-Chief Executive Officer | SSale | −100.0K | $29.84 | −$2.98M | −2.8%3.51M after | 2 lots10b5-1 |
| Oct 7, 2026 (view filing)4:00 PM ET | Oct 5 | 2 days | Milne George M JrDirector | SSale | −30.0K | $27.70 | −$830.9K | −3.7%782.9K after | 10b5-1 |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Bedrosian Camille LChief Medical Officer | SSale | −10.0K | $32.40 | −$324.9K | −3.5%278.1K after | 2 lots |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Frates James MChief Financial Officer | SSale | −10.8K | $32.36 | −$349.8K | −4.4%233.6K after | 2 lots |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Mazzariello GinaChief Legal Officer | SSale | −9.54K | $32.46 | −$309.5K | −4.8%190.8K after | 2 lots |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Klee Justin B.Co-Chief Executive Officer | SSale | −30.5K | $32.18 | −$980.3K | −0.8%3.61M after | 2 lots |
| Sep 14, 2026 (view filing)4:00 PM ET | Sep 10 | 4 days | Cohen Joshua BCo-Chief Executive Officer | SSale | −30.5K | $32.19 | −$980.5K | −0.8%3.61M after | 2 lots |
| Jul 13, 2026 (view filing)4:00 PM ET | Jul 9-10 | 4 days | Mazzariello GinaChief Legal Officer | SSale | −30.0K | $17.96 | −$538.9K | −14.3%179.1K after | 2 lots10b5-1 |
Top 10 13F holders, Q2 2026
See all 206 holdersThe largest institutional positions in Amylyx Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FMR LLC | 16,727,909 | $300.4M | 0.01% | +97,368+0.6% | Added |
| BlackRock, Inc. | 8,827,085 | $158.5M | 0.00% | −1,7510.0% | Reduced |
| Perceptive Advisors LLC | 8,334,882 | $149.7M | 2.32% | +50,000+0.6% | Added |
| TCG Crossover Management, LLC | 6,243,812 | $112.1M | 2.70% | 00.0% | Unchanged |
| Commodore Capital LP | 5,650,000 | $101.5M | 6.04% | 00.0% | Unchanged |
| Jupiter Topco LLC | 5,236,102 | $94.0M | 0.04% | +5,236,102 | New |
| Saturn V Capital Management LLC | 4,624,101 | $83.0M | 11.91% | +274,216+6.3% | Added |
| Vanguard Capital Management LLC | 4,224,224 | $75.9M | 0.00% | +82,649+2.0% | Added |
| Morgan Stanley | 3,130,808 | $56.2M | 0.00% | +955,261+43.9% | Added |
| Driehaus Capital Management LLC | 3,036,970 | $54.5M | 0.32% | +49,823+1.7% | Added |
Holders of 5% or more of AMLX
See all 5 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Amylyx Pharmaceuticals, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| FMR LLC | 13G/A | 15.00%16.5M shares | +4.30 ppfrom 10.70% | Oct 7, 20252 filings | Feb 5, 2026 | SEC |
| Perceptive Advisors LLC | 13G/A | 7.50%8.28M shares | −0.70 ppfrom 8.20% | Jun 21, 20228 filings | May 15, 2026 | SEC |
| BlackRock, Inc. | 13G/A | 7.10%7.78M shares | +1.60 ppfrom 5.50% | Jul 17, 20252 filings | Jan 21, 2026 | SEC |
| TCG Crossover GP II, LLC | 13G/A | 5.70%6.24M shares | – | Aug 26, 20242 filings | Feb 17, 2026 | SEC |
| Commodore Capital LP | 13G | 5.10%5.65M shares | New | Nov 17, 20251 filing | Nov 17, 2025 | SEC |
Politician trades
All politician trades in AMLX1 member of Congress reported 1 trade in Amylyx Pharmaceuticals, Inc. since 2020. Newest filings:
| Filed | Politician | Type | Amount |
|---|---|---|---|
| Nov 16, 2022 |  Chris Jacobs House · NY | Buy | $1K-$15K |
House · NY · Nov 16, 2022
Buy$1K-$15K